Repligen | RGEN - Net Income


Repligen reported $5.01M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Agilent USD 339M 34M Mar/2026
Align Technology USD 108.29M 4.48M Jun/2026
Bio Techne USD 51.05M 13.04M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Bruker USD -62.9M 66.4M Jun/2026
Charles River Laboratories USD -1.48M 13.36M Jun/2026
Danaher USD 870M 159M Jun/2026
Dentsply International USD -10M 136M Mar/2026
General Electric Aerospace USD 2.37B 466M Jun/2026
Henry Schein USD 94M 13M Jun/2026
Illumina USD 207M 73M Jun/2026
IQVIA Holdings USD 256M 18M Jun/2026
Mettler Toledo International USD 232.9M 63.44M Jun/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
OraSure Technologies USD -19.29M 5.57M Dec/2025
Pacific Biosciences Of California USD -40.37M 2.37M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
Repligen USD 5.01M 3.32M Jun/2026
Revvity USD 51.82M 11.1M Jun/2026
Standard Biotools USD 127.07M 107.78M Mar/2026
Thermo Fisher Scientific USD 1.74B 85M Jun/2026
Waters USD -136M 64M Jun/2026
West Pharmaceutical Services USD 154M 15.2M Jun/2026